Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · APGE · as of Sep 30, 2025
Ownership Breakdown
182
Institutional Holders
▼ 14 vs Q2
$2.37B
Total Inst. Value
▼ $144.23M vs Q2
61.90M
Shares Outstanding
freeFloat 92.01%
59.58M
13F Shares Held
▲ 1.75M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
APGE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VR ADVISER, LLC biological products, (no diagnostic substances) | 8.49M | 14.54% | 14.54% | $337.44B | Nov 14, 2025 | — held |
FMR LLC biological products, (no diagnostic substances) | 6.92M | 11.84% | 11.84% | $274.79B | Nov 13, 2025 | ▲ 9.4K |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 4.72M | 8.08% | 8.08% | $187.67B | Nov 14, 2025 | ▲ 918.0K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 2.71M | 4.64% | 4.64% | $107.75B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.69M | 4.60% | 4.60% | $106.72B | Nov 12, 2025 | ▲ 123.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.25M | 3.84% | 3.84% | $89.22B | Nov 7, 2025 | ▲ 136.7K |
DRIEHAUS CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.16M | 3.69% | 3.69% | $85.76B | Nov 14, 2025 | ▼ 152.3K |
FAIRMOUNT FUNDS MANAGEMENT LLC biological products, (no diagnostic substances) | 2.05M | 3.51% | 3.51% | $81.39B | Nov 14, 2025 | — held |
STATE STREET CORP biological products, (no diagnostic substances) | 1.66M | 2.83% | 2.83% | $65.77B | Nov 14, 2025 | ▲ 396.3K |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 1.52M | 2.60% | 2.60% | $60.46B | Nov 14, 2025 | ▲ 563.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+5.60M shares5
New Positions
first time holders13
Decreased
−1.79M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.81M
+5.60M / −1.79M
Net new holders
+19
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
APGE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
21
Sell transactions
0.19
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Dambkowski Carl Chief Medical Officer | Jun 3, 2026 | Sale | 5,500 | $78.71 | $432.9K | 205.6K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | May 13, 2026 | Sale | 18,659 | $82.05 | $1.53M | 1.12M | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | May 13, 2026 | Sale | 1,341 | $82.58 | $110.7K | 1.12M | Form 4 ↗ |
Dambkowski Carl Chief Medical Officer | May 6, 2026 | Sale | 3,700 | $83.92 | $310.5K | 208.8K | Form 4 ↗ |
Dambkowski Carl Chief Medical Officer | May 6, 2026 | Sale | 1,800 | $84.60 | $152.3K | 207.0K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 811 | $81.02 | $65.7K | 174.6K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 900 | $82.60 | $74.3K | 173.7K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | May 1, 2026 | Sale | 289 | $83.16 | $24.0K | 173.4K | Form 4 ↗ |
Henderson Jane Chief Financial Officer | Apr 16, 2026 | Sale | 2,000 | $90.00 | $180.0K | 175.4K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS Chief Executive Officer | Apr 8, 2026 | Sale | 17,800 | $82.48 | $1.47M | 1.14M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Apogee Therapeutics, Inc. (APGE) is primarily owned by institutional investors, who hold approximately 96.3% of total shares outstanding. Company insiders own approximately 7.99%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Apogee Therapeutics, Inc. is VR ADVISER, LLC, holding approximately 8.49 million shares — equal to 14.54% of outstanding shares — as of September 30, 2025.
A total of 182 institutional investors currently hold APGE stock, with a combined institutional value of approximately $2.37 billion as of the most recent 13F filing period.
Frequently asked questions
APGE ownershipApogee Therapeutics, Inc. (APGE) is primarily owned by institutional investors, who hold approximately 96.3% of shares. The largest shareholder is VR ADVISER, LLC with a 14.54% stake. Company insiders hold 7.99%. Data sourced from SEC Form 13F as of September 30, 2025.